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The intake of a fructose-rich diet (FRD) in the normal female rat induces features similar to those observed in the humanmetabolic
syndrome phenotype. We studied the impact of FRD administration to mothers on pregnancy outcome. On gestational day (Gd)
zero rats were assigned to either group: ad libitum drinking tap water alone (normal diet, ND) or containing fructose (10% w/vol;
FRD) through pregnancy; all rats were fed a Purina chow diet ad libitum ND and FRD rats were daily cotreated or not with
metformin (60mg/Kg/day oral; ND + MF and FRD + MF) and submitted to a high glucose load test on Gd 14. Additionally,
placentas from different groups were studied on Gd 20. Data indicated that: (1) although FRD rats well tolerated glucose overload,
their circulating levels of insulin were significantly higher than in ND rats; (2) the mesometrial triangle blood vessel area was
significantly lower in placentas from FRD than ND dams; (3) the detrimental effects of FRD administration to mothers were
ameliorated by metformin cotreatment. Our study suggests that excessive intake of fructose during pregnancy enhanced the risk
for developing gestational diabetes and subsequent preeclampsia, and that metformin prevented the poor pregnancy outcome
induced by FRD.
1. Introduction
The prevalence of gestational diabetes mellitus (GDM) has
significantly increased during the last decades [1], and
offspring born to mothers with GDM present a significantly
increased risk of developing obesity and type 2 diabetes
mellitus (T2DM) [2, 3]. Maternal anthropometric factors
(e.g., prepregnancy body weight (BW), adiposity weight gain
during pregnancy) account for the variance in offspring BW
and adiposity at birth [1, 4], and on other risk factors as well
[5, 6]. However, maternal nutrition is a highly important
conditioning factor of fetal growth. GDM is characterized
by impaired glucose tolerance/decreased insulin sensitivity,
and mothers with GDM have an increased risk of developing
preeclampsia (PE) [7, 8]. Although the pathogenesis of PE
still remains unclear, it is accepted that PE is an endothelial
cell disorder associated with marked maternal and neonatal
morbidity [9]. On the other hand, insulin effectiveness
and angiogenesis [10–12] are key factors for the control
of endothelial cell function. Consequently, the presence of
decreased insulin sensitivity in the mother may enhance
the defects in angiogenic function [13, 14], leading to an
increased risk of PE.
Maternal nutritional disturbances during critical devel-
opmental periods [15–17] are known to raise the offspring’s
risk of developing obesity and metabolic disorders in adult
life [17–19]. One component that has currently been mod-
ified in diets is carbohydrates, mainly sucrose and fructose.
Although fructose lacks any short-term stimulatory effect
on insulin and leptin production [20], excessive fructose
intake through the diet without appropriate pancreatic and
adiposity responses could lead to long-term detrimental
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effects on the regulation of energy metabolism. Although
nowadays the total daily caloric intake by the individual
has risen, the per capita fructose intake (namely, from
high fructose corn syrup and, to a lesser extent, fruits and
vegetables) drastically increased [20] from 64 to 81 g/day
during the last decades. This behavioral change enhanced the
prevalence of several metabolic disorders [21]. We recently
reported that the intake of a fructose-rich diet (FRD) for
a short period of time enhances oxidative stress [22] and
induces several features of the human metabolic syndrome
phenotype in normal [23, 24] rats. Moreover, overweight
development resulted in the male offspring nursed by dams
fed an FRD during the lactation period [17]. However, only
few studies [25, 26] have been devoted to better examine the
impact of FRD intake on the dam’s physiology.
The objective of the present study was to explore the
impact of the intake of FRD, combined or not with oral
metformin (an enhancer of insulin sensitivity) treatment,
on pregnancy outcome. For this aim we studied in dams
fed an FRD, treated or not with metformin, metabolic
responses to glucose overload (at middle-late pregnancy)
and placental functionality (at late pregnancy). A group of
dams with inhibited angiogenesis, an accepted model of rat
preeclampsia [27], was run in parallel.
2. Materials and Methods
2.1. Animals and Experimental Designs. Randomly cycling
virgin adult female rats (Sprague-Dawley) were individually
caged and allowed to mate for 24 hours. Rats displaying
spermatozoa at their vaginal smears were considered preg-
nant (gestational day zero). Animals were employed and
experimented by following protocols for animal use from the
NIH guidelines for care and use of experimental animals.
All experiments received approval from our Institutional
Committee on Animal Experimentation. Pregnant rats were
randomly allocated in five experimental groups: (a) ad
libitum fed with Purina rat chow and tap water for drinking
(normal diet; ND); (b) ad libitum fed with Purina rat
chow and tap water containing D(−) Fructose (Biopack,
Argentina, 10% w/v) in the drinking water (fructose rich
diet; FRD) [17]; (c) similar to ND rats but orally co-treated
with metformin (MF; Craveri Lab., Argentina; at the dose
50mg/Kg/day [28], dissolved in the drinking water, ND +
MF dams); (d) similar to FRD rats and co-treated with
MF as mentioned above (FRD + MF); (e) additionally, for
comparison purposes only, a group of mothers fed an ND
were treated i.p., on gestational day (Gd) 5, with a general
inhibitor of angiogenesis (suramin, Alexis Biochemicals,
Enzo Life Sciences, USA, at a 100mg/Kg dose; SUR + ND
dams) [27].
2.1.1. i.v. Glucose Tolerance Test (GTT) at Middle-Late Preg-
nancy (Experiment 1). On the morning of Gd 14, dams
from different experimental groups were lightly anesthetized
with ketamine and submitted to an i.v. (through the right
jugular vein) high glucose load test (2 g glucose per Kg/BW)
[17]. Blood samples were withdrawn before (sample time
zero) and several times (5, 15, 30, 45, and 60 minutes)
after glucose administration. Plasma glucose concentrations
were determined by a commercial (Wiener Lab., Argentina)
enzymatic-colorimetric assay. The circulating concentrations
of insulin were determined by a specific radioimmunoassay
previously described [17].
2.1.2. Analysis of Placental Function at Late Pregnancy (Exper-
iment 2). In this experiment, additional groups (ND, FRD,
ND +MF, FRD + MF, and SUR +ND) of dams were studied.
On the morning of Gd 20, rats were weighed and submitted
to laparatomy (under light ketamine anesthesia). Viable
fetuses were counted, removed, and weighed. Placentas were
immediately dissected from random positions on each side-
horn, weighed, and fixed for histological studies as described
by Nash et al. [27].
2.2. Histological Studies in Placental Tissues. Placentas were
dehydrated in graded ethanol series and embedded in
paraffin according to a standard protocol. The entire placenta
was sectioned into 7mm thick sections, mounted on glass
slides, and stained with hematoxylin-eosin and periodic
acid-schiff (PAS). PAS staining visualizes structures with a
high proportion of carbohydrate components (i.e., glycogen,
glycoprotein, and proteoglycans) such as connective tissues,
mucus, and basal laminae. Hence, it facilitates the identi-
fication of maternal vessels in the mesometrial triangle. In
the PAS-stained placenta, randomly chosen slides were used
for stereological evaluation of the area occupied by vessels
compared with the total area of the mesometrial triangle.
Morphometric measurements were performed using a Carl
Zeiss microscope, a color monitor, and optimas software.
The slides were scanned at a magnification of 40x and the
total area of maternal vessel volume was measured on square
fields running through the section and completely covering
the mesometrial triangle area. Vessel area (in percentage
of the total area) was used to estimate vessel volume in
each experimental group. One operator performed all the
measurements using a double-blind system.
2.3. Statistical Analysis. Data (expressed as means ± SEM)
were analyzed by ANOVA either two-factor (diet-treatment)
or with repeated measures, followed by post hoc compar-
isons with Fisher’s test [24].
3. Results
3.1. Effect of Fructose Rich Diet Intake and Metformin
Treatment on i.v. High Glucose Load Test in 14-Day-Pregnant
Rats. The aim of Experiment 1 was focused on revealing
whether the intake of an FRD, through the first 14 days of
gestation, is a modifying factor of metabolic responses to
glucose overload. While dams’ body weight values and body
weight gain did not differ among groups on both Gd 0 and
Gd 14 (Table 1), the 14-day average of total calorie intake
was slightly (P < 0.05 versus ND values) enhanced in FRD
mothers, regardless of MF co-treatment (Table 2).
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Table 1: Body weight values (BW, in grams) of dams, recorded on gestational day (Gd) zero, fourteen, and twenty. The percent of increase
in BWs (in accordance with corresponding BWs on Gd 0) on Gd 14 and Gd 20 is also depicted. Values are means ± SEM (n= 14/16 rats on
Gd 0; n= 7/8 rats on Gd 14 and Gd 20).
BW Gd 0 BW Gd 14 % increase Gd 14 BW Gd 20 % increase Gd 20
ND 246.2± 9.9 286.5± 9.6 16.8± 2.9 342.5± 13.9 38.9± 3.5
FRD 241.1± 6.1 286.9± 6.8 19.9± 2.1 346.6± 11.7 43.2± 2.1
ND+MF 245.9± 7.2 286.8± 6.2 16.9± 2.5 345.5± 14.4 40.3± 2.4
FRD+MF 228.8± 5.7 273.8± 3.3 19.9± 2.6 338.9± 9.3 44.1± 5.1
SUR+ND 244.9± 5.9 273.6± 6.7 14.2± 1.9 326.8± 12.9 33.4± 3.5
Table 2: Average of daily energy intake (in cal per day, expressed as
total and accordingly to the source derived from: food and fluid) for
both 1–14- and 1–20-day periods in different experimental groups
of dams. Values are means± SEM (n = 14/16 rats on Gd 0; n = 7/8
rats on Gd 14 and Gd 20).
14-day energy intake 20-day energy intake
Total 91.1± 3.9 101.8 ± 8.1
ND Food 91.1± 3.9 101.8 ± 8.1
Fluid — —
Total 114.9± 2.6∗ 123.7± 4.3∗
FRD Food 84.7± 3.2 87.2± 3.7
Fluid 31.4± 2.6 34.1± 3.1
Total 97.2± 4.1 103.7± 5.4
ND+MF Food 97.2± 4.1 103.7± 5.4
Fluid — —
Total 109.1± 3.3+ 129.3± 2.8+
FRD+MF Food 79.5± 4.1 82.5± 8.9
Fluid 29.6± 2.4 30.6± 4.3
Total 86.9± 4.2 96.3± 4.7
SUR+ND Food 86.9± 4.2 96.3± 4.7
Fluid — —
∗P < 0.05 versus ND values.
+P < 0.05 versus MF+ND values.
Metabolic data indicated that on Gd 14, the nonfasting
(basal, time zero values) peripheral levels of glucose and
insulin were similar in all groups examined (Figures 1(a)
and 1(c)). The profile of circulating glucose concentrations
during the whole test showed that peak values occurred
5min after glucose load in all groups examined (P < 0.05
versus respective basal values). While in FRD, FRD + MF,
and SUR + ND dams 60min plasma glucose levels remained
significantly (P < 0.05) higher than the respective basal
values; conversely, in ND and ND + MF rats those values
were back to their respective basal values (Figure 1(a)). The
analysis of the areas under the curve (AUC) of glucose values
indicated that a significant (P < 0.05 versus ND values)
reduction in this parameter accounted only in ND + MF
dams (Figure 1(b)). Regarding plasma insulin levels, while
in ND, ND + MF and SUR + ND groups peak plasma
levels occurred 5min after glucose load, such a parameter
was delayed upto time 15min in FRD and FRD + MF
dams (Figure 1(c)) On time 60min after glucose, circulating
insulin concentrations were either back to (FRD, FRD + MF,
and SUR + ND) or even lower than (ND, ND + MF)
their respective basal values (Figure 1(c)). It should be
noted, however, that on this time, plasma insulinemia was
significantly (P < 0.05) higher in FRD than in ND dams.
These differences can be clearly observed when the AUCs of
plasma insulin concentrations are examined. In fact, the AUC
of circulating insulin values were significantly (P < 0.05)
higher in FRD than in ND dams (Figure 1(d)). Interestingly,
MF treatment in dams fed an FRD partially prevented the
enhanced insulin demand induced by the high glucose-load,
althoughMF by itself did notmodify overall insulin secretion
in ND dams (Figure 1(d)). Finally, the peripheral parameters
analyzed in SUR + ND dams indicated that they normally
managed glucose homeostasis (Figures 1(a) and 1(b)), but
it occurred at the expense of enhanced glucose-stimulated
insulin release (Figures 1(c) and 1(d)).
3.2. Impact of Fructose Rich Diet Intake Alone or Combined
with Metformin Treatment on Anthropometric Characteristics
and Pregnancy Outcome on Gestational Day 20. Changes in
body characteristics (BW and weight gain; Table 1) and total
caloric intake (Table 2) on Gd 20 were quite similar to those
found on Gd 14 (see also Tables 1 and 2). After laparatomy,
we found that litter size and placental tissue weight did not
differ among groups (Table 3). Conversely, fetuses from FRD
dams were significantly (P < 0.05 versus ND) heavier than
the normal ones, even when as a ratio with the corresponding
placental weight (Table 3). MF treatment in ND dams
rendered lighter (P < 0.05) fetuses than those recorded in
ND mothers (Table 3), although this difference no longer
exists after being expressed in relation to the corresponding
placental weight (Table 3). Interestingly, the enhancement in
fetuses BW (and in the relation between individual BW and
placental weight) induced by FRD intake was fully prevented
by co-treating FRD dams with MF (Table 3). Angiogenesis-
inhibited dams displayed light fetuses (Table 3). Finally,
means of the number of reabsorptions were similar in all
groups (ranging between 0.32 and 0.93 re-absorptions per
dam; n = 10/14 mothers group).
3.3. Fructose Rich Diet Intake-Induced Placental Dysfunction
in the 20-Day-Pregnant Rat: Beneficial Effect of Metformin
Treatment. Then we examined the effects of FRD intake
through 20 days of the gestational period, on placental
functionality (Experiment 2). Placentas obtained of mothers
from all groups on Gd 20 displayed a similar general
morphology, with a large labyrinth with an adjacent
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Figure 1: Circulating glucose (d) and insulin (c) levels before (sample time zero), and several times after i.v. glucose (2 g/Kg BW)
administration in 14-day-pregnant ND (open circles), FRD (closed circles), MF + ND (open squares), MF + FRD (closed squares), and
ND + SUR (closed triangles) rats. The areas under the curves (AUC) of plasma glucose (b) and insulin (d) concentrations throughout the
test are also displayed. (Values are means ± SEM, n = 6/7 dams per group). ∗P < 0.05 versus ND.
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Figure 2: Representative placental mesometrial triangle (MMT) area of implanted offspring in 20-day-pregnant ND (a), FRD (c), MF + ND
(b),MF + FRD (d), andND+ SUR (e) rats stained with PAS (L: labyrinth; Bars: 200 μm). Arrows show vessel area (×4). Insets: corresponding
MMT area at a higher magnification (10x). Maternal vessel area (in percentage) on gestational day 20 in the different groups of dams (f;
values are means ± SEM, n = 9 specimens per group). ∗P < 0.05 versus ND values.
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Table 3: Litter size (n= 10–14 mothers per group), fetuses’ body weight (n= 46–70 fetuses from 6-7 mothers per group) and placenta weight
(n= 12–20) obtained from different groups of mothers on Gd 20. Values means ± SEM.
Litter size Fetuses BW (grams) Placenta weight (grams) Fetuses BW: placental weight
ND 11.3 ± 0.51 3.49 ± 0.05 0.68 ± 0.05 4.73 ± 0.32
FRD 11.4 ± 0.62 3.68 ± 0.04∗ 0.75 ± 0.08 6.39 ± 0.39∗
ND+MF 11.2 ± 0.53 3.36 ± 0.05∗ 0.71 ± 0.02 4.85 ± 0.42
FRD+MF 10.2 ± 0.86 3.33 ± 0.03∗+ 0.78 ± 0.06 4.65 ± 0.38+
SUR+ND 10.3 ± 0.67 3.35 ± 0.04∗ 0.66 ± 0.05 4.97 ± 0.46
∗P < 0.05 versus ND values.
+P < 0.05 versus FRD values.
trophospongium area (Figure 2, panels a–e). The mesome-
trial triangle was filled with decidual tissue and contained
numerous PAS-positive arteries with endotrophoblast inva-
sion. The total vessel area in placentas from FRD dams was
significantly (P < 0.05) lower than that measured in ND
rats (Figure 2(f)). Interestingly, in mothers fed an FRD and
co-treated with MF, total blood vessel area was normally
preserved (Figure 2(f)); thus indicating the effectiveness of
MF treatment on FRD intake-induced placental dysfunction.
Conversely, this parameter remained unaltered in dams fed
anND and co-treated withMF (see also Figure 2(f)). Accord-
ingly to a previous study [27], the total placental blood vessel
area in SUR + ND dams resulted also significantly (P <
0.05 versus ND group values) diminished, reaching a similar
percentage of that recorded in FRD specimens (Figure 2(f)).
4. Discussion
The current data suggest that rats fed an FRD through
pregnancy are at a high risk for developing GDM and
subsequent PE. This notion is supported by two key findings:
(a) an early (Gd 14) enhancement in high-glucose load-
induced insulin secretion in plasma; (b) a distorted placental
function observed at a late stage (Gd 20) of pregnancy.
Highly important is the finding that these deleterious effects
of FRD administration to dams was overridden by co-
treatment with a low oral metformin dose.
We have previously addressed that nonpregnant rats fed
an FRD during 3 weeks, developed high plasma levels of
fatty acids, triglycerides, and inflammatory adipokines, as
well as distorted adipose tissue morphology and function
[24], with being these metabolic-endocrine abnormalities
being common to those ascribed to the human metabolic
syndrome phenotype [29]. In the present study we extended
the information regarding the detrimental effects of FRD
administered to pregnant rats. Of relevance is that the
undesirable effects induced by the FRD were fully overridden
by metformin. Indeed, as observed in non-pregnant normal
rats [24], an enhanced insulin secretion in plasma occurred
after glucose overload in FRD dams, thus clearly indicating
that pregnant FRD rats developed substantial changes in
peripheral insulin sensitivity, being the pancreatic reserve
still capable for maintaining glucose homeostasis. This fact
put in evidence the severity of the allostatic condition
(FRD) during middle-late (Gd 14) pregnancy, and it is
indicative for, although incomplete (e.g., FRD dams did not
display any evidence of intolerance to glucose overload), the
development of GDM. GDM incidence directly correlates
with maternal body weight, in both human [30] and rodents
[31]; however, we found that even at a normal body
weight range, FRD dams are at a higher risk of GDM.
Moreover, we found that treating dams fed an FRD with
metformin, the enhanced demand in insulin release after
high glucose load was completely abolished, indicating that
MF is a highly effective treatment for assuring a normal
pancreatic β-cell response in mothers at a high risk of
GDM. In this regard, recent studies in pregnant women
with GDM indicate thatMF treatment effectively ameliorates
pregnancy outcome [32]. In addition, we now provide data
regarding the effect of an early inhibition of angiogenesis on
carbohydrate metabolism in dams. In fact, suramin-treated
mothers displayed an increased insulin demand in order to
maintain glucose homeostasis during the high glucoseload
test, thus clearly indicating that a diminished tissue blood
supply has taken place in these dams.
As occurring in humans, FRD mothers were at a high
risk for subsequent development of PE. Indeed, on Gd
20, we observed that FRD dams displayed a significantly
reduced placental blood vessel area, parameter that was at
a similar level in suramin-treated dams, an openly accepted
rat model for rat PE [27]. It is plausible to expect that FRD-
induced impaired insulin sensitivity could be a modifying
factor of placental angiogenesis, due to the well-known
pro-angiogenic effect of insulin [10–14] and its inhibitory
activity on cell ephrin-B2 gene expression [33]. Thus, it could
be expected that the impaired insulin sensitivity installed
in FRD dams is responsible, at least in part, for reduced
placental blood vessel area. This presumption finds support
in the similarity of placental data obtained in suramin-
treated and FRD dams. Indeed, it has been showed that
suramin treatment in dams drastically reduced placental and
renal blood vessel areas, being these parameters indicative
for the hypertensive state developed by these dams [34].
Interestingly, and in accordance with its improving effect
on glucose homeostasis, metformin treatment in FRD dams
fully prevented placental dysfunction.
Finally and important to remark is the fact that the main
index of abnormal pregnancy outcome that we found in
FRD dams was the enhanced fetuses’ body weight on Gd
20, regardless of any dam’s overweight. It is accepted that
during GDM, the compensatory mother’s hyperinsulinemia
is the most important signal causing macrosomic offspring
[35]. Despite the placental dysfunction found in our FRD
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mothers, the enhanced insulin secretion operating for the
maintenance of glucose homeostasis could be cooperating
for the enhanced fetuses’ body weight [35], an abnormality
overridden by metformin treatment in FRD dams. In this
regard, it is known that GDM directly correlates with
high body weight of newborns [36]. It has been reported
that when GDM women are treated with metformin, a
compound readily crossing the placenta [37], the incidence
of both macrosomic rate and large for gestational age
neonates is reduced [38].
In conclusion, our data strongly suggest that the intake
of an FRD during pregnancy induced early (Gd 14) changes
in peripheral insulin sensitivity, that later (Gd 20) results
in a high risk for the development of placental dysfunction
and litter morbidity. Of relevance, the oral co-treatment
withmetformin counteracted the undesirable effects induced
by the intake of FRD through pregnancy. It remains to be
examined whether neonates born to FRDmothers are at high
risk for further development of type 2 DM and/or obesity,
and the effectiveness of metformin treatment in FRD dams
on those litter’s risks.
Acknowledgments
This work was supported by grants from CONICET (PIP
2009-0704) and FONCYT (PICT 2007-1051) of Argentina,
and Fondation pour la Recherche en Endocrinologie (FPRE
2011-2012) of Switzerland. The authors wish to thank Mrs.
S.H. Rogers for reviewing the manuscript.
References
[1] P. M. Catalano, J. P. Kirwan, S. M. Haugel-De, and J. King,
“Gestational diabetes and insulin resistance: role in short-
and long-term implications for mother and fetus,” Journal of
Nutrition, vol. 133, no. 5, pp. 1674S–1683S, 2003.
[2] B. L. Silverman, T. A. Rizzo, N. H. Cho, and B. E. Metzger,
“Long-term effects of the intrauterine environment: the
northwestern university diabetes in pregnancy center,” Dia-
betes Care, vol. 21, no. 2, pp. B142–B149, 1998.
[3] D. J. Pettitt, R. G. Nelson, M. F. Saad, P. H. Bennett, and W. C.
Knowler, “Diabetes and obesity in the offspring of Pima Indian
women with diabetes during pregnancy,” Diabetes Care, vol.
16, no. 1, pp. 310–314, 1993.
[4] B. R. Vohr, S. T. McGarvey, and R. Tucker, “Effects of maternal
gestational diabetes on offspring adiposity at 4–7 years of age,”
Diabetes Care, vol. 22, no. 8, pp. 1284–1291, 1999.
[5] A. S. Kvehaugen, L. F. Andersen, and A. C. Staff, “Anthropom-
etry and cardiovascular risk factors in women and offspring
after pregnancies complicated by preeclampsia or diabetes
mellitus,” Acta Obstetricia et Gynecologica Scandinavica, vol.
89, no. 11, pp. 1478–1485, 2010.
[6] I. M. Bernstein and P. M. Catalano, “Examination of factors
contributing to the risk of cesarean delivery in women with
gestational diabetes,” Obstetrics and Gynecology, vol. 83, no. 3,
pp. 462–465, 1994.
[7] M. I. Schmidt, B. B. Duncan, A. J. Reichelt et al., “Gestational
diabetes mellitus diagnosed with a 2-h 75-g oral glucose tol-
erance test and adverse pregnancy outcomes,” Diabetes Care,
vol. 24, no. 7, pp. 1151–1155, 2001.
[8] M. Wolf, L. Sandler, K. Mun˜oz, K. Hsu, J. L. Ecker, and R.
Thadhani, “First trimester insulin resistance and subse-
quent preeclampsia: a prospective study,” Journal of Clinical
Endocrinology and Metabolism, vol. 87, no. 4, pp. 1563–1568,
2002.
[9] R. Thadhani, J. L. Ecker, W. P. Mutter et al., “Insulin resistance
and alterations in angiogenesis: additive insults that may lead
to preeclampsia,” Hypertension, vol. 43, no. 5, pp. 988–992,
2004.
[10] E. Chou, I. Suzuma, K. J.Way et al., “Decreased cardiac expres-
sion of vascular endothelial growth factor and its receptors in
insulin-resistant and diabetic states: a possible explanation for
impaired collateral formation in cardiac tissue,” Circulation,
vol. 105, no. 3, pp. 373–379, 2002.
[11] M. Montagnani, L. V. Ravichandran, H. Chen, D. L. Esposito,
and M. J. Quon, “Insulin receptor substrate-1 and phosphoin-
ositide-dependent kinase-1 are required for insulin-stimulated
production of nitric oxide in endothelial cells,” Molecular
Endocrinology, vol. 16, no. 8, pp. 1931–1942, 2002.
[12] D. Vicent, J. Ilany, T. Kondo et al., “The role of endothelial
insulin signaling in the regulation of vascular tone and insulin
resistance,” Journal of Clinical Investigation, vol. 111, no. 9, pp.
1373–1380, 2003.
[13] F. C. Luft, “Soluble endoglin (sEng) joins the soluble fms-like
tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule,”
Nephrology Dialysis Transplantation, vol. 21, no. 11, pp. 3052–
3054, 2006.
[14] N. C. Kappas, G. Zeng, J. C. Chappell et al., “The VEGF recep-
tor Flt-1 spatially modulates Flk-1 signaling and blood vessel
branching,” Journal of Cell Biology, vol. 181, no. 5, pp. 847–858,
2008.
[15] J. K. Hamilton, E. Odrobina, J. Yin, A. J. Hanley, B. Zinman,
and R. Retnakaran, “Maternal insulin sensitivity during preg-
nancy predicts infant weight gain and adiposity at 1 year of
age,” Obesity, vol. 18, no. 2, pp. 340–346, 2010.
[16] M. S. Patel and M. Srinivasan, “Metabolic programming due
to alterations in nutrition in the immediate postnatal period,”
Journal of Nutrition, vol. 140, no. 3, pp. 658–661, 2010.
[17] A. Alzamendi, D. Castrogiovanni, R. C. Gaillard, E. Spinedi,
and A. Giovambattista, “Increased male offspring’s risk of
metabolic-neuroendocrine dysfunction and overweight after
fructose-rich diet intake by the lactating mother,” Endocrinol-
ogy, vol. 151, no. 9, pp. 4214–4223, 2010.
[18] P. D. Taylor and L. Poston, “Developmental programming of
obesity in mammals,” Experimental Physiology, vol. 92, no. 2,
pp. 287–298, 2007.
[19] I. C. McMillen and J. S. Robinson, “Developmental origins of
the metabolic syndrome: prediction, plasticity, and program-
ming,” Physiological Reviews, vol. 85, no. 2, pp. 571–633, 2005.
[20] S. S. Elliott, N. L. Keim, J. S. Stern, K. Teff, and P. J. Havel,
“Fructose, weight gain, and the insulin resistance syndrome,”
American Journal of Clinical Nutrition, vol. 76, no. 5, pp. 911–
922, 2002.
[21] G. A. Bray, S. J. Nielsen, and B. M. Popkin, “Consumption of
high-fructose corn syrup in beverages may play a role in the
epidemic of obesity,” American Journal of Clinical Nutrition,
vol. 79, no. 4, pp. 537–543, 2004.
[22] O. R. Rebolledo, C. A. Marra, A. Raschia, S. Rodriguez, and
J. J. Gagliardino, “Abdominal adipose tissue: early metabolic
dysfunction associated to insulin resistance and oxidative
stress induced by an unbalanced diet,” Hormone and Metabolic
Research, vol. 40, no. 11, pp. 794–800, 2008.
[23] A. Alzamendi, A. Giovambattista, A. Raschia et al., “Fructose-
rich diet-induced abdominal adipose tissue endocrine
8 ISRN Endocrinology
dysfunction in normal male rats,” Endocrine, vol. 35, no. 2,
pp. 227–232, 2009.
[24] A. Alzamendi, D. Castrogiovanni, H. H. Ortega, R. C. Gaillard,
A. Giovambattista, and E. Spinedi, “Parametrial adipose tissue
and metabolic dysfunctions induced by fructose-rich diet
in normal and neonatal-androgenized adult female rats,”
Obesity, vol. 18, no. 3, pp. 441–448, 2010.
[25] K. G. Koski andM. A. Fergusson, “Amniotic fluid composition
responds to changes in maternal dietary carbohydrate and
is related to metabolic status in term fetal rats,” Journal of
Nutrition, vol. 122, no. 2, pp. 385–392, 1992.
[26] S. Rawana, K. Clark, S. Zhong, A. Buison, S. Chackunkal, and
K. L. C. Jen, “Low dose fructose ingestion during gestation
and lactation affects carbohydrate metabolism in rat dams
and their offspring,” Journal of Nutrition, vol. 123, no. 12, pp.
2158–2165, 1993.
[27] P. Nash, P. Wentzel, S. Lindeberg et al., “Placental dysfunction
in Suramin-treated rats—a new model for pre-eclampsia,”
Placenta, vol. 26, no. 5, pp. 410–418, 2005.
[28] B. Yilmaz, A. Sucak, S. Kilic et al., “Metformin regresses
endometriotic implants in rats by improving implant levels
of superoxide dismutase, vascular endothelial growth factor,
tissue inhibitor of metalloproteinase-2, and matrix metallo-
proteinase-9,” American Journal of Obstetrics and Gynecology,
vol. 202, no. 4, pp. 368.e1–368.e8, 2010.
[29] J. L. Bartha, F. Gonza´lez-Bugatto, R. Ferna´ndez-Macı´as, N.
L. Gonza´lez-Gonza´lez, R. Comino-Delgado, and B. Hervı´as-
Vivancos, “Metabolic syndrome in normal and complicated
pregnancies,” European Journal of Obstetrics Gynecology and
Reproductive Biology, vol. 137, no. 2, pp. 178–184, 2008.
[30] K. S. Gibson, T. P. Waters, and P. M. Catalano, “Maternal
weight gain in women who develop gestational diabetes mel-
litus,” Obstetrics and Gynecology, vol. 119, no. 3, pp. 560–565,
2012.
[31] K. Holemans, S. Caluwaerts, L. Poston, and F. A. Van Assche,
“Diet-induced obesity in the rat: a model for gestational dia-
betes mellitus,” American Journal of Obstetrics and Gynecology,
vol. 190, no. 3, pp. 858–865, 2004.
[32] J. C. Silva, D. R. Fachin, M. L. Coral, and A. M. Bertini, “.
Perinatal impact of the use of metformin and glyburide for the
treatment of gestational diabetes mellitus,” Journal of Perinatal
Medicine, vol. 40, pp. 225–228, 2012.
[33] U. Hiden, I. Lang, N. Ghaffari-Tabrizi, M. Gauster, U. Lang,
and G. Desoye, “Insulin action on the human placental endo-
thelium in normal and diabetic pregnancy,” Current Vascular
Pharmacology, vol. 7, no. 4, pp. 460–466, 2009.
[34] P. Nash, M. Olovsson, and U. J. Eriksson, “Placental dysfunc-
tion in Suramin-treated rats: impact of maternal diabetes and
effects of antioxidative treatment,” Journal of the Society for
Gynecologic Investigation, vol. 12, no. 3, pp. 174–184, 2005.
[35] N. A. Khan, “Role of lipids and fatty acids in macrosomic
offspring of diabetic pregnancy,” Cell Biochemistry and Bio-
physics, vol. 48, no. 2-3, pp. 79–88, 2007.
[36] A. Lapolla, M. G. Dalfra`, E. Ragazzi, A. P. De Cata, and D.
Fedele, “New international association of the diabetes and
pregnancy study groups (IADPSG) recommendations for
diagnosing gestational diabetes compared with former crite-
ria: a retrospective study on pregnancy outcome,” Diabetic
Medicine, vol. 28, pp. 1074–1077, 2011.
[37] B. Charles, R. Norris, X. Xiao, and W. Hague, “Population
pharmacokinetics of metformin in late pregnancy,” Therapeu-
tic Drug Monitoring, vol. 28, no. 1, pp. 67–72, 2006.
[38] P. Gandhi, R. Bustani, P. Madhuvrata, and T. Farrell, “Intro-
duction of metformin for gestational diabetes mellitus in
clinical practice: has it had an impact?” European Journal of
Obstetrics & Gynecology and Reproductive Biology, vol. 160, pp.
147–150, 2012.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
